- Wesana’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a microdose of psilocybin combined with cannabidiol, significantly reduced depressive behaviors in a validated animal model
- A single high dose of psilocybin alone demonstrated rapid, significant, and short acting improvement in depressive behaviors up to 14 days following administration
- Following the single high dose, the maintenance regimen of a microdose of psilocybin in combination with cannabidiol resulted in an additional and sustained 64% reduction in depressive behaviors relative to the psilocybin single high dose alone
CHICAGO and TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, has announced positive results of an animal study on a novel depression treatment protocol. Combining psilocybin and cannabidiol, the animal study, conducted by an independent global laboratory services provider, demonstrated considerable and sustained improvement in depressive behaviors.
Wesana’s novel and proprietary depression treatment protocol includes a single high dose of psilocybin followed by a maintenance regimen of a microdose of psilocybin combined with cannabidiol. In a validated preclinical animal model of depression, the maintenance regimen demonstrated up to 64% further improvement than those observed with a single high dose of psilocybin alone.
Furthermore, the maintenance regimen provided a sustained antidepressant effect after the single high dose of psilocybin. Wesana’s proprietary treatment protocol is currently being evaluated for the treatment of multiple mental health conditions including major depressive disorder associated with traumatic brain injury.
“The positive results of this study align with my individual experience and the improvements that I observed in my personal journey with depression. It’s thrilling to see our scientific data support Wesana’s mission to find more effective treatments for the millions of individuals suffering from the symptoms of traumatic brain injury including depression,” said Daniel Carcillo, Wesana founder and Chief Executive Officer.
Dr. Mark Wingertzahn, Wesana’s Chief Scientific Officer, added “This is a great step forward in establishing the scientific evidence to support the utility of a combination product including psilocybin and cannabidiol in the treatment of depression and other unmet medical needs. Additionally, these data provide fundamental, independent scientific support for the ongoing drug development program for SANA-013.”
Please refer to the Company’s management’s discussion and analysis dated November 29, 2021, available on the Company’s profile on www.sedar.com for additional information as to the Company’s drug development program and the steps required to be completed for the Company to be able to commence phase I clinical trials.
On behalf of the Board of Directors:
“Daniel Carcillo”, Chief Executive Officer
About Wesana Health.
Wesana Health helps people transcend barriers in mental health and performance. We innovate in care development through our therapies and patent-pending protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model. Learn more at www.wesanahealth.com.
Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to future partnerships, collaborative research and the focus of the Company’s business. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance regarding the participation in, or success of, partnerships or collaborative research or that the Company will continue its business as described above. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Readers are encouraged to refer to the Listing Statement filed on Company’s profile on SEDAR at www.sedar.com for information as to the risks and other factors which may affect the Company’s business objectives and strategic plans.
psilocybin wesana health wesana cse-aion otc-shrmf cse-plnt cse-betr cse-drug cse-tium cse-pwr cse-code cse-cool cse-tmed cse-delc cse-cbdt cse-enbi cse-ftrp cse-gblc cse-havn cse-holl cse-lobe cse-wuhn cse-mset cse-neon cse-spor cse-nova cse-nm cse-eat cse-opti cse-buzz cse-phrm otc-hstrf otc-vggf otc-betrf otc-bnoef asx-bno otc-bmbif otc-cntfm otc-cpivf otc-bkllf otc-clabf otc-cophf asx-cph neo-cybn otc-clxpf otc-evahf otc-ehvvf otc-delcf otc-epwcf otc-entbf otc-ftrpf otc-regrf nasdaq-gbnh tsxv-gtms otc-havlf otc-gtsif otc-mcurf neo-mcur neo-mmed otc-mmedf otc-msstf otc-mine otc-mycof otc-nmdbf otc-trmnf otc-nmlsf otc-nvmdf otc-lkysf cve-numi otc-splif otc-lmllf otc-phrrf cve-psyb otc-psycf cse-psyc cse-psyg otc-prxtf cse-pull otc-truff cse-trip otc-rwbyf cse-rwb otc-rvvtf cse-rvv otc-rmanf cve-litt nasdaq-seel otc-silo otc-shgff cse-shg otc-trssf cse-ter otc-pemtf cse-tbi otc-trypf cse-tyrp otc-xphyf cse-xphy nasdaq-cmps tsxv-cln otc-alid asx-ihl